Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 11 #1
TickerHIL [NYSE]
CompanyHill International, Inc.
IndustryEngineering & Construction
Market Cap192.43MEPS (ttm)-0.00
P/E-EPS this Y48.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y29.40%
P/S0.48EPS next 5Y25.00%
P/B1.94EPS Q/Q380.90%
Dividend-Sales Q/Q4.10%
Insider Own3.60%Inst Own56.30%
Insider Trans0.00%Inst Trans-4.29%
Short Float0.41%EarningsAug 09/a
Analyst Recom-Target Price-
Avg Volume912.26K52W Range1.18 - 3.39
Aug-30-22 04:05PMHill International to Provide Project Management and Supervision Consultancy Services for the International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt GlobeNewswire
Aug-27-22 12:16AMGISI and Hill International announce enhancements to their strategic merger agreement GlobeNewswire
Aug-16-22 09:36PMGISI and Hill International Announce Strategic Merger Business Wire
Aug-16-22 08:57PMHill International to be Acquired by Global Infrastructure Solutions Inc. for $2.85 Per Share GlobeNewswire
Aug-09-22 04:05PMHill International Reports 2022 Second Quarter Financial Results GlobeNewswire
Aug-08-22 01:00PMHill International Announces Two Awards to Support Landmark Developments for Aldar Properties Projects in Abu Dhabi: The Grove and Al-Reeman GlobeNewswire
Aug-03-22 10:00AMHill International to Provide Project Management, Construction Management and Site Supervision Services for Four Seasons Hotel Luxor, Egypt GlobeNewswire
Aug-01-22 04:15PMHill International Schedules Release of Second Quarter 2022 Financial Results and Conference Call GlobeNewswire
Jul-20-22 02:46PMPE firm that owns Fort Worth architecture firm pitches acquisition of construction company American City Business Journals
Jul-19-22 07:00AMGodspeed Capital Proposes to Acquire Hill International For $143.9 Million in Cash Business Wire
Hill International, Inc. provides project and construction management, and other consulting services primarily for buildings, transportation, environmental, energy, and industrial markets. The company offers program management, project management, construction management, project management oversight, troubled project turnaround, staff augmentation, project labor agreement consulting, commissioning, estimating and cost management, and labor compliance and facilities management services. It primarily serves the United States federal, state, and local governments; other national governments; and the private sector. The company operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Hill International, Inc. was founded in 1976 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EVANS PAUL J.DirectorNov 15Buy2.229,99922,159425,000Nov 16 05:46 PM
EVANS PAUL J.DirectorSep 28Buy2.0410,72521,858415,001Sep 29 04:14 PM
CompanyForma Therapeutics Holdings, Inc.
Market Cap968.43MEPS (ttm)-4.00
P/E-EPS this Y-13.60%
Forward P/E-EPS next Y5.10%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.30EPS Q/Q-19.50%
Dividend-Sales Q/Q-
Insider Own0.90%Inst Own88.90%
Insider Trans0.00%Inst Trans0.16%
Short Float3.63%EarningsAug 05/b
Analyst Recom1.50Target Price29.43
Avg Volume1.33M52W Range4.95 - 25.21
Sep-07-22 12:37PMBiotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More Zacks
Sep-02-22 10:09AMNovo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition Zacks
Sep-01-22 04:10PMNovo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout Investor's Business Daily
Sep-01-22 02:36PMWhy Forma Therapeutics Holdings Stock Is On Fire Today Motley Fool
Sep-01-22 09:55AMAfter Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal Benzinga
Sep-01-22 09:21AMWatertown biotech acquired by Novo Nordisk for $1.1B American City Business Journals
Sep-01-22 09:01AMNovo Nordisk to Buy Forma Therapeutics in $1.1 Billion Deal Bloomberg
Sep-01-22 08:31AMUPDATE 1-Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal Reuters
Sep-01-22 08:18AMForma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion MarketWatch
Sep-01-22 08:12AMNovo Nordisk to acquire Forma Therapeutics in $1.1. billion deal Reuters
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Patrick F.SVP, Chief Medical OfficerApr 08Option Exercise5.0515,00075,750104,884Apr 14 06:10 PM
Kelly Patrick F.SVP, Chief Medical OfficerFeb 23Sale9.785,24551,28364,884Feb 25 05:08 PM
Lee Frank D.President and CEOFeb 23Sale9.7817,981175,80979,769Feb 25 05:08 PM
Potts JeannetteSee RemarksFeb 23Sale9.784,67245,68022,358Feb 25 05:01 PM
Shegog ToddSVP, Chief Financial OfficerFeb 23Sale9.785,68755,60522,813Feb 25 05:04 PM
CompanyIMARA Inc.
Market Cap51.03MEPS (ttm)-2.08
P/E-EPS this Y32.90%
Forward P/E-EPS next Y68.50%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.86EPS Q/Q41.40%
Dividend-Sales Q/Q-
Insider Own2.10%Inst Own59.50%
Insider Trans4.55%Inst Trans-2.82%
Short Float0.88%EarningsAug 05/b
Analyst Recom3.00Target Price1.20
Avg Volume1.69M52W Range0.97 - 4.62
Sep-07-22 03:35PMImara divests from sickle cell treatment research Yahoo Finance Video
Sep-07-22 09:05AMAfter Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge Benzinga
Aug-25-22 06:15AMA IMARA Inc. (NASDAQ:IMRA) insider increased their holdings by 195% last year Simply Wall St.
Jul-15-22 06:55AMWill IMARA (NASDAQ:IMRA) Spend Its Cash Wisely? Simply Wall St.
May-19-22 12:00PMWhat Makes IMARA Inc. (IMRA) a New Buy Stock Zacks
Apr-05-22 06:45AMImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
Mar-15-22 07:00AMImara Reports Full Year 2021 Financial Results and Business Highlights GlobeNewswire
Mar-09-22 06:24AM7 Biotech Stocks With Key Catalysts in March InvestorPlace
Mar-08-22 07:00AMImara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights GlobeNewswire
Feb-19-22 07:10AMDavid Mott Is The Independent Chairman of IMARA Inc. (NASDAQ:IMRA) And They Just Picked Up 144% More Shares Simply Wall St.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leonard Braden Michael10% OwnerJun 16Buy1.1183,19992,2433,017,774Jun 21 09:48 AM
Leonard Braden Michael10% OwnerJun 06Buy1.162,6303,0512,934,575Jun 07 04:12 PM
Leonard Braden Michael10% OwnerJun 03Buy1.1430,80034,9762,931,945Jun 07 04:12 PM
Leonard Braden Michael10% OwnerMay 17Buy1.2626,14532,8362,901,145May 18 11:00 AM
Leonard Braden Michael10% OwnerMay 16Buy1.1715,00017,5772,875,000May 18 11:00 AM
CompanyFirst Solar, Inc.
Market Cap14.53BEPS (ttm)1.76
P/E76.37EPS this Y17.40%
Forward P/E61.83EPS next Y2422.20%
PEG13.54EPS past 5Y25.30%
P/S5.86EPS next 5Y5.64%
P/B2.44EPS Q/Q-32.50%
Dividend-Sales Q/Q-1.30%
Insider Own0.30%Inst Own82.20%
Insider Trans-17.82%Inst Trans2.85%
Short Float4.91%EarningsJul 28/a
Analyst Recom2.70Target Price120.57
Avg Volume2.43M52W Range59.60 - 135.20
Sep-08-22Upgrade Goldman Sell → Buy $60 → $172
Sep-08-22 05:50AM3 Stocks to Buy If They Take a Dip Motley Fool
Sep-08-22 03:51AMGameStop, Asana, First Solar Rise Premarket; American Eagle Outfitters Falls Investing.com
Sep-07-22 06:42PMWhy First Solar Stock Climbed Today Motley Fool
Sep-04-22 05:16PMWhy First Solar Stock Rocketed More Than 28% in August Motley Fool
Sep-01-22 11:31AMWhy Is SunPower (SPWR) Up 7.9% Since Last Earnings Report? Zacks
Sep-01-22 09:56AMBiden praises U.S. investments by Micron, First Solar, Toyota, others: 'A direct result of my economic plan' MarketWatch
Sep-01-22 08:59AMThese 10 Renewable Energy Stocks Can Benefit as Europe Braces for Harsh Winter Insider Monkey
Aug-31-22 10:35AMFirst Solar Stock in 3 Minutes Motley Fool
Aug-31-22 09:44AMFirst Solar to Invest $1 Billion in New U.S. Factory Investopedia
Aug-31-22 08:52AMFirst Solar (FSLR) to Invest $1.2B to Boost Production Capacity Zacks
First Solar, Inc. provides photovoltaic (PV) solar energy solutions in the United State, Japan, France, Canada, India, Australia, and internationally. The company designs, manufactures, and sells cadmium telluride solar modules that converts sunlight into electricity. It serves developers and operators of systems, utilities, independent power producers, commercial and industrial companies, and other system owners. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar, Inc. was founded in 1999 and is headquartered in Tempe, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gloeckler MarkusChief Technology OfficerAug 18Sale118.7446555,2141,373Aug 19 04:03 PM
Gloeckler MarkusChief Technology OfficerAug 17Option Exercise0.0084402,217Aug 19 04:03 PM
Gloeckler MarkusChief Technology OfficerAug 17Sale115.1447855,0371,373Aug 19 04:03 PM
KENNEDY R CRAIGDirectorAug 15Sale117.4160070,44619,785Aug 17 04:27 PM
ANTOUN GEORGESChief Commercial OfficerAug 05Buy100.539,946999,87137,300Aug 05 06:04 PM
TickerGBT [NASD]
CompanyGlobal Blood Therapeutics, Inc.
Market Cap4.61BEPS (ttm)-5.00
P/E-EPS this Y-19.30%
Forward P/E-EPS next Y39.10%
PEG-EPS past 5Y-14.20%
P/S19.63EPS next 5Y37.00%
P/B37.77EPS Q/Q-12.60%
Dividend-Sales Q/Q50.40%
Insider Own1.90%Inst Own-
Insider Trans-2.96%Inst Trans2.59%
Short Float9.24%EarningsAug 08/a
Analyst Recom1.90Target Price66.63
Avg Volume3.25M52W Range21.65 - 73.02
Sep-08-22 08:00AMGBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference GlobeNewswire
Sep-07-22 11:30AMGlobal Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue? Zacks
Aug-30-22 05:47PMPotential sickle cell disease 'cure' jumps to clinic, yet investors remain cool American City Business Journals
Aug-29-22 08:00AMThese 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year Investor's Business Daily
Aug-22-22 11:08AMHow an unsolicited offer led to 11th-hour bids and the biggest Bay Area biotech deal of the year American City Business Journals
Aug-12-22 09:50AMPharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023 Zacks
Aug-09-22 04:46PMGet ready for more merger mania in the pharma sector for the rest of the year MarketWatch
Aug-09-22 03:59PMAs Covid Vaccine Boom Ends, Pfizer and Moderna Pursue Opposite Strategies Barrons.com
Aug-09-22 11:02AMGlobal Blood (GBT) to be Acquired by Pfizer, Misses on Earnings Zacks
Aug-08-22 04:07PMWhy Pfizer's $5.4 Billion GBT Takeover Is 'Mutually Beneficial' Investor's Business Daily
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farrow Jeffrey SChief Financial OfficerSep 01Sale68.0031,4412,137,9883,086Sep 06 07:00 PM
Habibizad NazilaSee RemarksAug 18Sale67.194,678314,3158,918Aug 19 12:31 PM
Svoronos DawnDirectorJun 21Sale27.241,90851,9835,376Jun 22 06:00 PM
Pizzo Philip A.DirectorJun 21Sale27.251,26034,3379,112Jun 22 06:00 PM
Morrison Scott WDirectorSep 09Sale30.214,800145,0033,037Sep 10 08:00 PM
CompanyChannelAdvisor Corporation
IndustrySoftware - Application
Market Cap656.69MEPS (ttm)1.28
P/E17.83EPS this Y139.10%
Forward P/E22.46EPS next Y21.29%
PEG2.23EPS past 5Y46.70%
P/S3.82EPS next 5Y8.00%
P/B4.04EPS Q/Q-59.10%
Dividend-Sales Q/Q3.10%
Insider Own2.80%Inst Own95.40%
Insider Trans-2.97%Inst Trans-4.42%
Short Float3.07%EarningsAug 09/b
Analyst Recom2.00Target Price23.50
Avg Volume356.47K52W Range11.89 - 29.42
Sep-07-22 05:14PMTuberville and Pelosi: Two Recent "Well-Timed" Congressional Trades TheStreet.com
Sep-06-22 07:50PMCommerceHub plans to acquire ChannelAdvisor Corp. for $663M American City Business Journals
Sep-06-22 03:57PMCommerceHub set to acquire ChannnelAdvisor for $663 million Yahoo Finance Video
Sep-06-22 03:02PMIf CommerceHub buys ChannelAdvisor - here's who gets richer American City Business Journals
Sep-06-22 11:55AMWhy ChannelAdvisor Stock Jumped This Morning Motley Fool
Sep-06-22 09:07AMChannelAdvisor Shares Pop On Takeover Offer At 57% Premium Benzinga
Sep-06-22 09:04AMCommerceHub to take ChannelAdvisor private in $663M deal American City Business Journals
Sep-06-22 08:10AMChannelAdvisor shares rally on deal to sell it self to private equity-backed CommerceHub MarketWatch
Sep-06-22 07:30AMCommerceHub to Acquire ChannelAdvisor for $23.10 per share PR Newswire
Aug-23-22 08:00AMChannelAdvisor Named Amazon Ads Advanced Partner PR Newswire
ChannelAdvisor Corporation, together with its subsidiaries, provides software-as-a-service (SaaS) solutions in the United States and internationally. The company's SaaS is a cloud platform that helps brands and retailers to improve their e-commerce operations, expand to new channels, and grow sales. Its suite of solutions includes various platform modules, including Marketplaces module that connects customers to third-party marketplaces, and allows brands and distributors to manage purchase orders, shipment notifications, stock quantities, and invoices for multiple retail dropship partners; Digital Marketing module that creates, manages, and evaluates advertising using a variety of ad formats across multiple channels; Shoppable Media module that allows brands to provide web visitors to purchase using dynamic links to in-stock retail product pages or carts, or with information on where products can be purchased from local retail stores; and Brand Analytics module, which helps brands for e-commerce channels with actionable insights into how products are performing across thousands of retailer websites and marketplaces. Its customers include online businesses of brands and retailers, as well as advertising agencies that use its solutions on behalf of their clients. The company was incorporated in 2001 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Spitz David JPresident and CEOAug 29Option Exercise8.6431,250270,000419,734Aug 30 08:52 AM
WINGO M SCOTDirectorAug 22Sale15.353,25049,88828,001Aug 23 06:20 AM
WINGO M SCOTDirectorJul 20Sale14.913,25048,45831,251Jul 20 04:12 PM
WINGO M SCOTDirectorJun 21Sale14.483,25047,06034,501Jun 21 04:04 PM
WINGO M SCOTDirectorMay 13Sale12.8815,000193,20037,751May 17 04:06 PM
CompanyChemoCentryx, Inc.
Market Cap3.69BEPS (ttm)-1.89
P/E-EPS this Y-123.80%
Forward P/E-EPS next Y59.10%
PEG-EPS past 5Y-17.00%
P/S98.93EPS next 5Y-
P/B15.51EPS Q/Q20.90%
Dividend-Sales Q/Q555.60%
Insider Own4.20%Inst Own84.00%
Insider Trans-6.74%Inst Trans4.91%
Short Float11.10%EarningsAug 09/a
Analyst Recom1.60Target Price52.00
Avg Volume2.37M52W Range14.95 - 51.78
Sep-07-22 11:30AMWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report? Zacks
Sep-01-22 10:59AMHow Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger American City Business Journals
Aug-29-22 08:00AMThese 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year Investor's Business Daily
Aug-24-22 08:30AMChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences GlobeNewswire
Aug-16-22 12:00PMHere's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy Zacks
Aug-16-22 09:55AMChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy? Zacks
Aug-15-22 10:35AMAmgen Inc. -- Moody's assigns Baa1 rating to Amgen's notes; stable outlook Moody's
Aug-12-22 06:05AMThe Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals Zacks
Aug-09-22 08:30AMChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call GlobeNewswire
Aug-05-22 05:16PMAmgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx Investor's Business Daily
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KANAYA SUSAN MEVP, CFO and Sec.Aug 16Option Exercise10.8619,898216,092111,215Aug 18 04:48 PM
KANAYA SUSAN MEVP, CFO and Sec.Aug 16Sale50.9519,8981,013,79391,317Aug 18 04:48 PM
KANAYA SUSAN MEVP, CFO and Sec.Aug 04Option Exercise6.5046,298300,805137,615Aug 08 07:33 PM
Schall Thomas J.President and CEOAug 04Option Exercise14.28130,0001,856,4002,523,352Aug 08 07:41 PM
Tyree James LDirectorAug 04Sale50.2210,000502,2009,138Aug 08 07:27 PM
CompanyAtlas Air Worldwide Holdings, Inc.
IndustryAirports & Air Services
Market Cap2.83BEPS (ttm)14.50
P/E6.89EPS this Y19.70%
Forward P/E7.06EPS next Y-14.13%
PEG0.69EPS past 5Y56.90%
P/S0.64EPS next 5Y10.00%
P/B0.99EPS Q/Q-24.90%
Dividend-Sales Q/Q19.10%
Insider Own0.60%Inst Own-
Insider Trans-22.57%Inst Trans-0.13%
Short Float12.41%EarningsAug 05/b
Analyst Recom2.70Target Price98.50
Avg Volume943.97K52W Range58.70 - 101.62
Sep-06-22 08:30AMIs the Options Market Predicting a Spike in Atlas Air (AAWW) Stock? Zacks
Aug-25-22 09:40AMIs Atlas Air Worldwide Holdings (AAWW) Outperforming Other Transportation Stocks This Year? Zacks
Aug-19-22 09:40AMAre Investors Undervaluing Atlas Air Worldwide Holdings (AAWW) Right Now? Zacks
Aug-18-22 08:20AMImplied Volatility Surging for Atlas Air Worldwide (AAWW) Stock Options Zacks
Aug-16-22 12:00PMHere's Why Atlas Air Worldwide (AAWW) is a Great Momentum Stock to Buy Zacks
Aug-15-22 11:34PMShould You Still Consider Investing in Atlas Air Worldwide (AAWW)? Insider Monkey
Aug-11-22 12:11PMAtlas Air Extends Long-Standing Pact With This Australian Air Freight Carrier Benzinga
Aug-11-22 08:00AMAtlas Air Extends Partnership with Qantas Freight GlobeNewswire
Aug-10-22 08:50AMWhy Fast-paced Mover Atlas Air (AAWW) Is a Great Choice for Value Investors Zacks
Aug-09-22 09:40AMHas Atlas Air Worldwide Holdings (AAWW) Outpaced Other Transportation Stocks This Year? Zacks
Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services. It operates through two segments, Airline Operations and Dry Leasing. The company offers outsourced cargo and passenger aircraft operating solutions, including contractual service arrangements, such as the provision of aircraft; and value-added services, including crew, maintenance, and insurance to aircraft and other customers. It also provides cargo and passenger aircraft charter services to the U.S. Military Air Mobility Command, charter brokers, freight forwarders, direct shippers, airlines, manufacturers, sports teams and fans, and private charter customers; and cargo and passenger aircraft and engines dry leasing services. In addition, the company offers administrative and management support services, and flight simulator training services. It also serves express delivery providers, e-commerce retailers, and airlines. The company has operations in Africa, Asia, Australia, Europe, the Middle East, North America, and South America. Atlas Air Worldwide Holdings, Inc. was founded in 1992 and is headquartered in Purchase, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DIETRICH JOHN WPresident & CEOAug 01Sale84.1339,4633,320,10164,989Aug 03 05:41 PM
Kokas Adam RichardEVP, GC & Secty.Mar 21Sale88.459,975882,28933,356Mar 23 07:38 AM
Steen MichaelEVP & CMOJan 12Sale87.506,688585,20068,451Jan 13 05:01 PM
Kokas Adam RichardEVP, GC & Secty.Jan 03Sale95.0110,348983,16321,954Jan 04 05:20 PM
Steen MichaelEVP & CMODec 15Sale87.5618,3581,607,50875,139Dec 16 05:59 PM
CompanyH.I.G. Acquisition Corp.
IndustryShell Companies
Market Cap454.45MEPS (ttm)0.39
P/E25.81EPS this Y160.10%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.31EPS Q/Q301.60%
Dividend-Sales Q/Q-
Insider Own0.39%Inst Own96.70%
Insider Trans0.00%Inst Trans1.63%
Short Float0.04%Earnings-
Analyst Recom-Target Price-
Avg Volume45.62K52W Range9.72 - 10.00
Oct-02-21 09:26AMHow Many H.I.G. Acquisition Corp. (NYSE:HIGA) Shares Do Institutions Own? Simply Wall St.
Apr-05-21 05:20AMHow Much Of H.I.G. Acquisition Corp. (NYSE:HIGA) Do Institutions Own? Simply Wall St.
H.I.G. Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Miami, Florida.
TickerYPF [NYSE]
CompanyYPF Sociedad Anonima
IndustryOil & Gas Integrated
Market Cap5.27BEPS (ttm)0.53
P/E12.48EPS this Y100.40%
Forward P/E3.10EPS next Y-29.65%
PEG-EPS past 5Y15.00%
P/S0.51EPS next 5Y-6.39%
P/B0.38EPS Q/Q-
Dividend-Sales Q/Q65.30%
Insider Own99.50%Inst Own47.70%
Insider Trans0.00%Inst Trans62.20%
Short Float5.01%Earnings-
Analyst Recom3.70Target Price4.35
Avg Volume2.35M52W Range2.82 - 6.64
Sep-08-22 09:00AMIs Most-Watched Stock YPF Sociedad Anonima (YPF) Worth Betting on Now? Zacks
Aug-31-22 08:50AMHere Is Why Bargain Hunters Would Love Fast-paced Mover YPF Sociedad Anonima (YPF) Zacks
Aug-30-22 09:15AMYPF Sociedad Anonima (YPF) Soars to 52-Week High, Time to Cash Out? Zacks
Aug-24-22 12:00PMHere's Why YPF Sociedad Anonima (YPF) is a Great Momentum Stock to Buy Zacks
Aug-22-22 06:03AMBeat the Market the Zacks Way: Dillard's (DDS), Sotherly Hotels (SOHO), Casey's (CASY) in Focus Zacks
Aug-15-22 09:49AMBest Value Stocks to Buy for August 15th Zacks
Aug-15-22 08:50AMWhy Fast-paced Mover YPF Sociedad Anonima (YPF) Is a Great Choice for Value Investors Zacks
Aug-15-22 08:20AMNew Strong Buy Stocks for August 15th Zacks
Jul-26-22 05:50PMYPF Sociedad Anonima (YPF) Gains As Market Dips: What You Should Know Zacks
Jul-22-22 06:00PMYPF Sociedad Anonima (YPF) Flat As Market Sinks: What You Should Know Zacks
YPF Sociedad Anonima, an energy company, engages in the oil and gas upstream and downstream activities in Argentina. The company's upstream operations include the exploration, development, and production of crude oil, natural gas, and NGLs. Its downstream operations include the refining, marketing, transportation, and distribution of oil, petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels, as well as in gas separation, natural gas distribution operations, and power generation. As of December 31, 2021, it had interests in 119 oil and gas fields; approximately 643 million barrels (mmbbl) of oil; and approximately 2,447 billion cubic feet (bcf) of gas. It also had a retail distribution network of 1,654 YPF-branded service stations; and 18 exploration permits. In addition, the company owns and operates three refineries with combined annual refining capacity of approximately 120 mmbbl; approximately 2,800 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; and crude oil tankage of approximately 7 mmbbl, as well as maintains terminal facilities at five Argentine ports. Further, it participates in 21 power generation plants with an aggregate installed capacity of 3,091 megawatts; offers diesel, fertilizers, lubricants, phytosanitary products, and ensiling bags; and supplies diesel, gasoline, fuel oil, coal, asphalts, paraffin, and sulfur, CO2, decanted oil, and aromatic extract. The company was founded in 1977 and is headquartered in Buenos Aires, Argentina.